A. Fukazawa

Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study

Yoichiro Yoshida, Takeshi Yamada, Hirohiko Kamiyama et al. · International Journal of Clinical Oncology · 2020 · 44 citations

Medicine, Oncology, Pharmacology +10

Mass spectrometric profiling of DNA adducts in the human stomach associated with damage from environmental factors

Ippei Ohnishi, Yuji Iwashita, Yuto Matsushita et al. · Genes and Environment · 2021 · 29 citations · Full text

Medicine, Biochemistry, Oncology +6

Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)

Hiroshi Matsuoka, Takeshi Yamada, Ryo Ohta et al. · International Journal of Clinical Oncology · 2022 · 21 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

The Pre-treatment Lymphocyte-to-Monocyte Ratio Predicts Efficacy in Metastatic Colorectal Cancer Treated With TAS-102 and Bevacizumab

Hidekazu Kuramochi, Takeshi Yamada, Yoichiro Yoshida et al. · Anticancer Research · 2021 · 20 citations · Full text

Medicine, Immunology, Oncology +16

Mismatch repair proteins immunohistochemical null phenotype in colon medullary carcinoma

Kyota Tatsuta, Mayu Sakata, Moriya Iwaizumi et al. · Clinical Journal of Gastroenterology · 2021 · 12 citations

Medicine, Oncology, Pathology +16